论文部分内容阅读
入院前心脏停搏经复苏的病人,慢性定性心律失常及复发心脏停搏的发生率甚高。这些患者的慢性无症状性室性心律失常对各种抗心律失常药物的标准剂量呈抗药性。本文报道根据血浆浓度调节剂量,观察血浆治疗浓度与其抑制慢性无症状性室性心律失常和反复性心脏停搏的关系。方法:16例入院前心脏停搏经复苏后住院并存活出院的病人,其中8例随访12个月以上未再复发心脏停搏,另8例在随访期间再度发生心脏停搏。其中6人死亡,2例再度复苏成功并存活至今。此16例在随访中皆有慢性无症状性室性心律失常。两组病人均用膜活性抗心律失常药物奎尼丁或普鲁卡因酰胺治疗。以奎尼丁2.3～6.0微克/毫升及普鲁卡因酰胺4～8微克/毫升作为治疗水平血浆浓度。每日用药量按之调节。在长期用药期间每月用24小时Holter心电图监护一次及每日通过电话传送30～60秒的
Pre-admission cardiac arrest resuscitated by patients with chronic cardiac arrhythmia and recurrent cardioversion a high incidence. Chronic asymptomatic ventricular arrhythmias in these patients are resistant to standard doses of various antiarrhythmic drugs. This paper reports the dose adjusted according to the plasma concentration to observe the plasma concentration and its inhibition of chronic asymptomatic ventricular arrhythmias and recurrent cardiac arrest relationship. Methods: Sixteen patients who had been hospitalized and survived before resuscitation underwent cardioplegic arrest were retrospectively studied. Among them, 8 patients were followed up for more than 12 months without recurrence of cardiac arrest and the other 8 patients had cardiac arrest again during follow - up. Six of them were dead and two recovered again and survived to this day. All 16 patients had chronic asymptomatic ventricular arrhythmias during follow-up. Both groups were treated with quinidine, a membrane-active antiarrhythmic drug, or procainamide. Quinidine 2.3 ~ 6.0μg / ml and procainamide 4 ~ 8μg / ml as the therapeutic level of plasma concentration. Daily dosage according to the regulation. During the long-term medication with 24-hour Holter ECG once a month and daily by telephone transmission 30 to 60 seconds